Gamma-secretase inhibitor does not modulate angiogenesis in colon adenocarcinoma in obese mice

Bratislava Medical Journal

Volumn 116, Issue 4, 2015, Pages 248-251

  Khazaei, M ^a   Kalantari, E ^b   Saeidi, H ^b   ShabaniKia, N ^b   Tahergorabi, Z ^a   Rashidi, B ^b   Dana, N ^c   Javanmard, S H ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adenocarcinoma; Angiogenesis; Obese; secretase

Indexed keywords

AMYLOID PRECURSOR PROTEIN SECRETASES; DIPEPTIDES; N-(N-(3,5-DIFLUOROPHENACETYL)ALANYL)PHENYLGLYCINE TERT-BUTYL ESTER;

ADENOCARCINOMA; ANIMALS; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; COMPLICATION; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MICE; MICE, OBESE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OBESITY; PATHOLOGY;

ADENOCARCINOMA; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; COLONIC NEOPLASMS; DIPEPTIDES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, OBESE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OBESITY;

EID: 84928560354     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2015_048     Document Type: Article

References (26)

1. Rehman AO, Wang CY. Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol 2006; 16 (6): 293-300.
2. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001; 69 (2-3): 135-144.
3. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66 (4): 649-661.
4. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006; 107 (6): 2223-2233.
5. Nakajima M, Yuasa S, Ueno M, Takakura N, Koseki H, Shirasawa T. Abnormal blood vessel development in mice lacking presenilin-1. Mech Dev 2003; 120 (6): 657-667.
6. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005; 94: 209-231.
7. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7 (5): 359-371.
8. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation 2002; 105 (18): 2133-2135.
9. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4 (8): 579-591.
10. Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J, Mullan M. Inhibition of angiogenesis and tumor growth by beta and gammasecretase inhibitors. Eur J Pharmacol 2005; 514 (1): 1-15.
11. Dovey HF, John V, Anderson JP, Chen LZ, de Saint AP, Fang LY et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76 (1): 173-181.
12. Gil-Ortega M, Stucchi P, Guzman-Ruiz R, Cano V, Arribas S, Gonzalez MC et al. Adaptative nitric oxide overproduction in perivascular adipose tissue during early diet-induced obesity. Endocrinology 2010; 151 (7): 3299-3306.
13. Jang EH, Park CS, Lee SK, Pie JE, Kang JH. Excessive nitric oxide attenuates leptin-mediated signal transducer and activator of transcription 3 activation. Life Sci 2007; 80 (7): 609-617.
14. Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hubschle T et al. Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther 2008; 325 (2): 370-379.
15. Jahng JW, Lee JY, Yoo SB, Kim YM, Ryu V, Kang DW et al. Refeeding-induced expression of neuronal nitric oxide synthase in the rat paraventricular nucleus. Brain Res 2005; 1048 (1-2): 185-192.
16. Maejima K, Nakano S, Himeno M, Tsuda S, Makiishi H, Ito T et al. Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complications 2001; 15 (3): 135-143.
17. Benkhoff S, Loot AE, Pierson I, Sturza A, Kohlstedt K, Fleming I et al. Leptin potentiates endothelium-dependent relaxation by inducing endothelial expression of neuronal NO synthase. Arterioscler Thromb Vasc Biol 2012; 32 (7): 1605-1612.
18. Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res 2006; 83 (5): 1005-1016.
19. Wu FT, Stefanini MO, Mac GF, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010; 14 (3): 528-552.
20. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nor JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 2010; 17 (3): 499-512.
21. Anagnostoulis S, Karayiannakis AJ, Lambropoulou M, Efthimiadou A, Polychronidis A, Simopoulos C. Human leptin induces angiogenesis in vivo. Cytokine 2008; 42 (3): 353-357.
22. Hoda MR, Popken G. Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells. BJU Int 2008; 102 (3): 383-388.
23. Zou Y, Cao Y, Yue Z, Liu J. Gamma-secretase inhibitor DAPT suppresses glioblastoma growth via uncoupling of tumor vessel density from vessel function. Clin Exp Med 2012.
24. Hayashi H, Nakagami H, Takami Y, Sato N, Saito Y, Nishikawa T et al. Involvement of gamma-secretase in postnatal angiogenesis. Biochem Biophys Res Commun 2007; 363 (3): 584-590.
25. Caiado F, Real C, Carvalho T, Dias S. Notch pathway modulation on bone marrow-derived vascular precursor cells regulates their angiogenic and wound healing potential. PLoS One 2008; 3 (11): e3752.
26. Cao L, Arany PR, Wang YS, Mooney DJ. Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. Biomaterials 2009; 30 (25): 4085-4093.